



Published in final edited form as:

ACS Catal. 2019 December 6; 9(12): 10721–10726. doi:10.1021/acscatal.9b03990.

A Bacterial β 1–3-Galactosyltransferase Enables Multigram-Scale Synthesis of Human Milk Lacto-*N*-tetraose (LNT) and Its Fucosides

John B. McArthur[†], Hai Yu[†], Xi Chen^{*}

Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, United States

Abstract

β 1–3-Linked galactosides such as Gal β 1–3GlcNAc β OR are common carbohydrate motifs found in human milk oligosaccharides (HMOs), glycolipids, and glycoproteins. Efficient and scalable enzymatic syntheses of these structures have proven challenging due to the lack of access to a highly active β 1–3-galactosyltransferase (β 3GalT) in large amounts. Previously reported *E. coli* β 3GalT (EcWbgO) has been identified as a limiting factor for producing a β 1–3-galactose-terminated human milk oligosaccharide lacto-*N*-tetraose (LNT) by fermentation. Here we report the identification of an EcWbgO homolog from *C. violaceum* (Cv β 3GalT) which showed a high efficiency in catalyzing the formation of LNT from lacto-*N*-triose (LNT II). With the highly active Cv β 3GalT, multigram-scale (>10 gram) synthesis of LNT from lactose was achieved using a sequential one-pot multienzyme (OPME) glycosylation process. The access to Cv β 3GalT enabled enzymatic synthesis of several fucosylated HMOs with or without further sialylation including LNFP II, S-LNF II, LNDFH I, LNFP V, and DiFuc-LNT. Among these, LNFP V and DiFuc-LNT would not be accessible by enzymatic synthesis if an active β 3GalT were not available.

Graphical Abstract

^{*}Corresponding Author: xiichen@ucdavis.edu.


[†]These authors contributed similarly to this work.

The authors declare no competing financial interest.

Supporting Information.

The Supporting Information is available free of charge on the ACS Publications website at DOI: <https://doi.org/10.1021/acscatal.9b03990>.

Supplemental figures and experimental details for cloning and characterization of Cv β 3GalT, as well as detailed synthetic procedures, nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS) data, and NMR spectra of products (PDF)



Keywords

biocatalysis; enzymatic synthesis; glycosyltransferase; human milk oligosaccharide; LNT

β 1–3-Linked galactosides such as Gal β 3GlcNAc β OR are common carbohydrate motifs found in human milk oligosaccharides (HMOs), glycolipids, and glycoproteins.^{1–3} Gal β 1–3GlcNAc-containing blood group epitopes Lewis b and sialyl Lewis a are tumor associated carbohydrate antigens (TACAs), and their upregulation on cancer cells is associated with poor cancer prognosis.⁴ Gal β 3GlcNAc β OR, which is called the Type 1 glycan structure, is also an important motif in HMOs, a group of more than 100 oligosaccharides naturally presented in human milk at a concentration ranging from 5 to 15 g L⁻¹.^{5–6} These compounds are non-digestible for human infants but have been found to contribute to the immediate and long-term benefits of breastfeeding, such as protecting breast-fed infants against infections and necrotizing enterocolitis,^{7–8} improving their intelligence, and reducing rates of childhood obesity, diabetes, leukemia, and sudden infant death syndrome.⁹ HMOs display prebiotic properties which enrich beneficial bacteria such as *B. infantis* in the gut,¹⁰ serve as host-cell receptor decoys to disrupt pathogen adhesion,^{11–12} modulate intestinal surface glycan expression,¹³ affect cell growth and differentiation,¹⁴ and provide nutrients for the development of the brain and cognition of infants.^{1, 5}

HMOs consist of galactoside core structures with or without fucosylation and/or sialylation.¹ Among the 20 HMO core structures that have been identified, 11 contain at least one type 1 glycan-terminated branch.¹ Lacto-*N*-tetraose (LNT, Gal β 3GlcNAc β 3Lac) is the simplest type 1 glycan HMO with a disaccharide unit Gal β 3GlcNAc β 1–3-linked to lactose (Lac, Gal β 4Glc), the conserved reducing end disaccharide moiety in all HMOs.¹⁵ LNT (1) and its fucosylated derivatives lacto-*N*-fucopentaose I (LNFP I, 8), LNFP II (2), lacto-*N*-difucosylhexaose I (LNDFH I, 4), and LNDFH II (7) (Figure 1) are among the most abundant HMOs.^{12, 16} While the type 1 glycan structures predominate in human milk, they are less abundant and sometimes are completely absent in the milk of other mammals.^{16–17} Investigating the biological functions of individual type 1 glycan-containing HMOs and their potential applications as prebiotics and antimicrobials requires access to sufficient amounts of structurally defined compounds.

Chemical synthesis of these compounds²¹ involves multiple protection and deprotection processes. Though promising, efforts for enzymatic synthesis of β 1–3-linked galactoside motifs have met limited success. *B. infantis* D-galactosyl- β 1–3-*N*-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) catalyzes the formation of β 1–3-galactosyl linkages to short GlcNAc or GalNAc-terminated acceptor substrates efficiently²² but longer oligosaccharides such as lacto-*N*-triose (LNT II) were not suitable acceptor substrates.^{22–23} Synthesis of LNT from LNT II with three equivalents of *ortho*-nitrophenyl- β -galactoside (Gal β oNP) by *Bacillus circulans* β 1–3-galactosidase (BcBgaC)-catalyzed transglycosylation resulted in only 20% yield.²⁴ Its glycosynthase mutant E233G generated products with the desired Gal β 3GlcNAc linkage in higher (59–86%) isolated yields using chemically synthesized α -galactopyranosyl fluoride as the donor substrate.²⁵ Recently an endoglycosynthase strategy was explored using an oxazoline derivative of Gal β 1–3GlcNAc as the donor substrate for *Bifidobacterium bifidum* JCM 1254 β -D-hexosaminidase mutants to form LNT, achieving around 30% yield with two of the designed mutants.²⁶

Efficient strategies for LNT production would be glycosyltransferase-mediated glycosylation using sequential one-pot multienzyme (OPME) reactions and fermentation,²⁷ both with *in situ* production of UDP-sugar donors. *E. coli* β 1–3-galactosyltransferase (EcWbgO) was found to be active in catalyzing the formation of LNT from lacto-*N*-triose (LNT II).²⁸ Metabolic engineering of *E. coli* to produce LNT by fermentation resulted in the production of 0.219 g L⁻¹ LNT using 1% glucose as the carbon source,²⁹ while the use of 1% galactose as the carbon source yielded 0.810 g L⁻¹ LNT.³⁰ In each case, EcWbgO was rate limiting, and its acceptor substrate LNT II (the intermediate for the formation of the desired LNT) was accumulated as the major product. The high K_M value (3.4 mM) of EcWbgO toward UDP-Gal was believed to hinder its activity.²⁸ Similarly, a strain of *E. coli* metabolically engineered to produce fucosylated LNT analogs accumulated LNT II intermediate and its α 1–3-fucoside, suggesting insufficient EcWbgO activity.³¹ Expression of EcWbgO as an N-terminal His₆-tagged or a C-terminal His₆-tagged fusion protein failed to produce detectable soluble proteins, but adding an N-terminal glutathione S-transferase (GST)-tag yielded 1.6 mg of purified fusion protein per liter culture.²⁸ Cleavage of the GST tag was inefficient and the resulting EcWbgO was inactive. Recently, the expression of EcWbgO with a C-terminal 245-amino acid sequence of *S. hyicus* lipase pre-propeptide at a level of 54.5 mg per liter was described.³² It has been used for synthesizing linear long-chain LNT using UDP-Gal^{33–34} but has not been applied in multigram-scale of LNT with *in situ* generation of UDP-Gal by either OPME synthesis or fermentation. We aimed to identify a new β 1–3-galactosyltransferase with a high expression level and improved activity.

To search for an efficient β 1–3-galactosyltransferase for LNT synthesis, we expected that a suitable candidate could be obtained from homologs of EcWbgO. Clustal Omega multiple sequence alignment³⁵ analysis of the BLAST³⁶ results for EcWbgO homologs led to the selection of four candidates (Figure S1) including *Chromobacterium violaceum* (Cv β 3GalT), *Pectobacterium parmentieri* (Pp β 3GalT), *Salmonella enterica* (Sev β 3GalT), and *Yersia intermedia* (Yi β 3GalT). Synthetic genes with codon optimization for *E. coli* expression were cloned into pET-22b(+) vector for expressing C-His₆-tagged fusion proteins. Of these four EcWbgO homologs, only Cv β 3GalT was expressed as a soluble protein in *E. coli* (Figure S2) and was therefore selected for additional characterization.

Cv β 3GalT was active in a broad pH range with optimal activities in the pH range of 6.5–9.5 (Figure S3). This broad pH tolerance is ideal for OPME reaction systems which involve numerous enzymes. Its activity was abolished in the presence of ethylenediaminetetraacetic acid (EDTA) or CaCl₂ and enhanced by MgCl₂ and MnCl₂ (Figure S4). Similar to the conditions for EcWbgO,²⁸ MnCl₂ resulted in a higher enzymatic activity for Cv β 3GalT than MgCl₂. Product was detected without the addition of a metal ion, and in the presence of LiCl, NaCl, or dithiothreitol (DTT), suggesting that Cv β 3GalT bond MgCl₂ or MnCl₂ tightly enough that the metal was not completely washed away during Ni²⁺-column purification.

Apparent kinetic constants for Cv β 3GalT (Table 1) were determined using LNT II- β ProNHfMoc as the acceptor and UDP-Gal as the donor. The catalytic efficiency of Cv β 3GalT with LNT II- β ProNHfMoc as the acceptor was about 23-fold greater than that of EcWbgO with LNT II as the acceptor,²⁸ which was mainly contributed by a 116-fold higher turnover rate of Cv β 3GalT. Furthermore, the binding affinity of EcWbgO toward its acceptor substrate LNT II is 62-fold greater than toward its donor substrate UDP-Gal,²⁸ which disfavors catalysis as glycosyltransferases follow an ordered sequential Bi-Bi mechanism in which the enzyme binds the nucleotide sugar before the acceptor for an effective catalytic process.³⁷ The property of EcWbgO with a higher affinity toward its acceptor substrate than its donor substrate may explain why EcWbgO performed poorly during metabolic engineering efforts to produce LNT. In contrast, Cv β 3GalT displayed a preference for binding UDP-Gal ($K_m = 0.23 \pm 0.06$ mM) over LNT II- β ProNHfMoc ($K_m = 0.74 \pm 0.07$ mM).

With Cv β 3GalT in hand as an excellent glycosyltransferase, preparative and large-scale syntheses of LNT from commercially available and inexpensive lactose were carried out using a sequential OPME glycosylation process.

As shown in Scheme 1, trisaccharide GlcNAc β 3Gal β 4Glc (LNT II) was initially synthesized in a 1.5-gram scale from lactose and *N*-acetylglucosamine (GlcNAc) using an OPME *N*-acetylglucosamine (GlcNAc)-activation and transfer system (**OPME 1**) containing *Bifidobacterium longum* strain ATCC55813 *N*-acetylhexosamine-1-kinase (BLNahK),³⁸ *Pasteurella multocida* *N*-acetylglucosamine uridylyltransferase (PmGlmU),³⁹ *Pasteurella multocida* inorganic pyrophosphatase (PmPpA),⁴⁰ and *Neisseria meningitidis* β 1–3-*N*-acetylglucosaminyltransferase (NmLgtA).⁴¹ An excellent 97% yield for purified LNT-II was achieved. LNT (Gal β 3GlcNAc β 3Gal β 4Glc) was then synthesized from LNT II and galactose in a 130-mg preparative scale with an excellent 99% yield using an OPME galactose (Gal)-activation and transfer system (**OPME 2**) containing *Streptococcus pneumoniae* TIGR4 galactokinase (SpGalK),⁴² *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP),⁴³ PmPpA, and Cv β 3GalT.

The efficiency of the sequential OPME process was further demonstrated in a multigram-scale synthesis of LNT. Trisaccharide LNT II was produced from 10 grams of lactose, GlcNAc (1.15 equiv.), and ATP and UTP (1.28 equiv. each) using the OPME GlcNAc-activation and transfer system. When the reaction reached completion as indicated by the complete consumption of lactose, the reaction mixture was concentrated and applied directly

without purification to the subsequent OPME C β 3GalT-containing galactosylation reaction with additional amounts of Gal (1.20 equiv.), ATP and UTP (1.30 equiv. each). A total consumption of LNT II intermediate was observed. A portion (1/12.5) of the reaction mixture was subjected to purification by a Dowex 1 \times 8–200 (formate form) anion exchange column and a Bio-Gel P-2 gel filtration column to produce pure LNT. A yield of 99.3% was determined for the synthesis of LNT from Lac with two OPME systems carried out in sequence. The sequential OPME process without the purification of LNT II intermediate is a highly effective approach to obtain large quantities of LNT in high yields.

In addition to LNT, the synthesis of fucosylated and/or sialylated HMOSs containing LNT core including LNFP II (**2**), S-LNF II (**3**), and LNDFH I (**4**) (Scheme 2) was explored.

Lacto-*N*-fucopentaose II (LNFP II, **2**) Gal β 3(Fuc α 4)GlcNAc β 3Gal β 4Glc is a pentasaccharide containing a fucose α 1–4-linked to the GlcNAc unit in LNT (**1**). The concentration of LNFP II in human milk was reported to be in the range of 0.14–1.25 g L⁻¹.⁴⁴ LNFP II was shown to protect human intestinal epithelial cells from *E. histolytica*-induced cytotoxicity by blocking the binding of the bacterium.⁴⁵ As shown in Scheme 2, LNFP II (**2**) was synthesized from LNT using an OPME fucosylation system (**OPME 3a**) containing a bifunctional *Bacteroides fragilis* L-fucokinase/GDP-fucose pyrophosphorylase (BfFKP),⁴⁶ PmPpA, and *Helicobacter pylori* UA948 α 1–3/4-fucosyltransferase (Hp3/4FT).¹⁸ When 1.1 equivalents of fucose (Fuc) was used, Hp3/4FT catalyzed the transfer of fucose selectively to the GlcNAc (instead of Glc) residue in LNT to form LNFP II (**2**) in 81% yield. As we reported previously,¹⁸ adding more than two equivalents of Fuc in the reaction system produced difucosylated LNDFH II Gal β 3(Fuc α 4)GlcNAc β 3Gal β 4(Fuc α 3)Glc (**7**), a hexasaccharide found in human milk at a concentration in the range 0.05 to 0.27 g L⁻¹.^{44, 47–48} The preference of Hp3/4FT towards fucosylation of GlcNAc-containing disaccharide Gal β 3GlcNAc β motif to the Glc-containing disaccharide Gal β 4Glc (Lac) motif in LNT is similar to what was observed previously¹⁸ for its preference in the Gal β 4GlcNAc β motif to the Gal β 4Glc (Lac) motif in lacto-*N*-neotetraose (LNnT), a type 2 glycan also found in HMOSs. Sialylfucosyllacto-*N*-tetraose (S-LNF II, **3**) Neu5Aca.3Gal β 3(Fuca.3)GlcNAc β 3Gal β 4Glc was subsequently synthesized from LNFP II (**2**) using an OPME α 2–3-sialylation system (**OPME 4**) containing *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS)⁴⁹ and *Pasteurella multocida* α 2–3-sialyltransferase 1 M144D mutant (PmST1 M144D).⁵⁰

Lacto-*N*-difuco-hexaose I (LNDFH I, **4**) Fuc α 2Gal β 3(Fuca4)GlcNAc β 3Gal β 4Glc, which has both α 1–2- and α 1–4-linked fucose residues (Scheme 2), has been found in human milk at a concentration of 0.32–1.40 g L⁻¹.^{44, 47, 51} It presents a terminal Lewis b structure that can bind to *H. pylori* and has been a candidate for developing potential therapeutics against *H. pylori* infection.^{11, 52} Attempts to fucosylate LNFP II (**2**) using an OPME fucosylation system (**OPME 3b**) containing *Thermosynechococcus elongates* α 1–2-fucosyltransferase (Te2FT)¹⁹ or *Escherichia coli* O126 α 1–2-fucosyltransferase (EcWbgL)^{53–54} were not successful, indicating that LNFP II (**2**) was not a suitable acceptor substrate for Te2FT or EcWbgL. Instead, LNDFH I (**4**) was successfully synthesized by altering the fucosylation sequence of LNT. First, LNT (**1**) was α 1–2-fucosylated at the terminal galactose (Gal) residue using the Te2FT-containing OPME system (**OPME 3b**) to produce LNFP I

Fuca₂Gal β 3GlcNAc β 3Gal β 4Glc (**8**)¹⁹ with an excellent 91% yield. Subsequently, LNFP I was modified with an α 1–4-linked fucose at the GlcNAc residue by the Hp3/4FT-containing OPME system (**OPME 3a**) in excellent (92%) yield. This demonstrated that LNFP I (**8**) was a suitable acceptor substrate for Hp3/4FT and the GlcNAc was the preferred fucosylation site of Hp3/4FT over the Glc in LNFP I (**8**).

Lacto-*N*-fucopentaose V (LNFP V, **5**) Gal β 3GlcNAc β 3Gal β 4(Fuca₃)Glc (Scheme 3) is another important HMOs. It is a pentasaccharide containing an α 1–3-linked fucose at the reducing end glucose (Glc) of LNT. LNFP V, along with other fucosylated HMOs, was shown to provide protection for infants of secretor mothers from necrotizing enterocolitis (NEC) and sepsis.⁵⁵ Direct fucosylation of LNT to obtain LNFP V (**5**) would be challenging due to the lack of a FucT to selectively add Fuc to the Glc of LNT (**1**). Hence, an alternative approach was carried out. As shown in Scheme 3, LNT II was fucosylated by the Hp3/4FT-containing OPME fucosylation system (**OPME 3a**) to produce Fuc-LNT II GlcNAc β 3Gal β 4(Fuca₃)Glc (**10**) in an excellent 98% yield. The tetrasaccharide was an excellent acceptor for Cv β 3GalT, and LNFP V (**5**) was synthesized readily in 98% yield using the Cv β 3GalT-containing OPME galactosylation system (**OPME 2**). LNFP V (**5**) was found not a suitable acceptor substrate of Te2FT, but a well-tolerated substrate for EcWbgL. Therefore, fucosylation of LNFP V (**5**) with a Fuc α 1–2-linked to the terminal Gal was achieved by EcWbgL-containing OPME system (**OPME 3b**) for the formation of difucosylated LNT (DiFuc-LNT, **6**) Fuca₂Gal β 3GlcNAc β 3Gal β 4(Fuca₃)Glc in 99% yield.

In conclusion, the newly discovered Cv β 3GalT is a highly efficient catalyst for the synthesis of LNT (**1**) and LNT-containing fucosylated and/or sialylated HMOs. LNT (**1**) was synthesized in a multigram (>10 grams) scale from inexpensive starting materials (lactose, GlcNAc, Gal, ATP, and UTP) using a highly efficient sequential OPME process and without purification of the trisaccharide intermediate LNT II. By designing the order of glycosylation, fucosylated LNT HMOs with different fucosylation linkages and with fucosylation at different sites were successfully synthesized in high yields. These included monofucosylated HMOs including LNFP II (**2**), its sialylated form S-LNF II (**3**), and LNFP V (**5**) as well as difucosylated HMOs such as LNDFH I (**4**) and its derivative DiFuc-LNT (**6**). As the Gal β 1–3GlcNAc linkage is common in HMOs and other human glycans such as sialyl Lewis a and Lewis b, Cv β 3GalT represents a valuable addition to the synthetic glycobiology toolbox. OPME systems are proven again as powerful approaches for synthesizing complex oligosaccharides.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

This work was supported by the United States National Institutes of Health (NIH) Common Fund Glycoscience Program grants U01GM120419 and U01GM125288. Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538.

REFERENCES

- (1). Yu H; Chen X CHAPTER 11: Enzymatic and Chemoenzymatic Synthesis of Human Milk Oligosaccharides (HMOS). in Synthetic Glycomes 2019, pp. 254–280.
- (2). Yu RK; Tsai YT; Ariga T; Yanagisawa M Structures, Biosynthesis, and Functions of Gangliosides—An Overview. *J. Oleo Sci* 2011, 60, 537–544. [PubMed: 21937853]
- (3). Holgersson J; Lofling J Glycosyltransferases Involved in Type 1 Chain and Lewis Antigen Biosynthesis Exhibit Glycan and Core Chain Specificity. *Glycobiology* 2006, 16, 584–593. [PubMed: 16484342]
- (4). Thurin M; Kieber-Emmons T SA-Le^a and Tumor Metastasis: The Old Prediction and Recent Findings. *Hybrid Hybridomics* 2002, 21, 111–116. [PubMed: 12031100]
- (5). Bode L Human Milk Oligosaccharides: Every Baby Needs A Sugar Mama. *Glycobiology* 2012, 22, 1147–1162. [PubMed: 22513036]
- (6). Rudloff S; Kunz C Milk Oligosaccharides and Metabolism in Infants. *Adv. Nutr* 2012, 3, 398S–405S. [PubMed: 22585918]
- (7). Neu J; Walker WA Necrotizing Enterocolitis. *N. Engl. J. Med* 2011, 364, 255–264. [PubMed: 21247316]
- (8). Lucas A; Cole TJ Breast Milk and Neonatal Necrotising Enterocolitis. *Lancet* 1990, 336, 1519–1523. [PubMed: 1979363]
- (9). Stuebe A The Risks of Not Breastfeeding for Mothers and Infants. *Rev. Obstet. Gynecol* 2009, 2, 222–231. [PubMed: 20111658]
- (10). German JB; Freeman SL; Lebrilla CB; Mills DA Human Milk Oligosaccharides: Evolution, Structures and Bioselectivity as Substrates for Intestinal Bacteria. *Nestle Nutr. Workshop Ser. Pediatr. Program* 2008, 62, 205–222.
- (11). Gustafsson A; Hultberg A; Sjoström R; Kacs Kovics I; Breimer ME; Boren T; Hammarström L; Holgersson J Carbohydrate-Dependent Inhibition of *Helicobacter pylori* Colonization using Porcine Milk. *Glycobiology* 2006, 16, 1–10. [PubMed: 16118287]
- (12). Kunz C; Rudloff S; Baier W; Klein N; Strobel S Oligosaccharides in Human Milk: Structural, Functional, and Metabolic Aspects. *Annu Rev Nutr* 2000, 20, 699–722. [PubMed: 10940350]
- (13). Angeloni S; Ridet JL; Kusy N; Gao H; Crevoisier F; Guinchard S; Kochhar S; Sigrist H; Sprenger N Glycoprofiling with Micro-arrays of Glycoconjugates and Lectins. *Glycobiology* 2005, 15, 31–41. [PubMed: 15342550]
- (14). Kuntz S; Kunz C; Rudloff S Oligosaccharides from Human Milk Induce Growth Arrest via G2/M by Influencing Growth-Related Cell Cycle Genes in Intestinal Epithelial Cells. *Br. J. Nutr* 2009, 101, 1306–1315. [PubMed: 19079835]
- (15). Kobata A Structures and Application of Oligosaccharides in Human Milk. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci* 2010, 86, 731–747.
- (16). Urashima T; Asakuma S; Leo F; Fukuda K; Messer M; Oftedal OT The Predominance of Type I Oligosaccharides is A Feature Specific to Human Breast Milk. *Adv. Nutr* 2012, 3, 473s–482s. [PubMed: 22585927]
- (17). Fushinobu S Conformations of The Type-1 Lacto-N-Biose I Unit in Protein Complex Structures. *Acta Crystallogr. F Struct. Biol. Commun* 2018, 74, 473–479. [PubMed: 30084396]
- (18). Yu H; Li Y; Wu Z; Li L; Zeng J; Zhao C; Wu Y; Tasnima N; Wang J; Liu H; Gadi MR; Guan W; Wang PG; Chen XH *pylori* alpha1–3/4-Fucosyltransferase (Hp3/4FT)-Catalyzed One-Pot Multienzyme (OPME) Synthesis of Lewis Antigens and Human Milk Fucosides. *Chem. Commun* 2017, 53, 11012–11015.
- (19). Zhao C; Wu Y; Yu H; Shah IM; Li Y; Zeng J; Liu B; Mills DA; Chen X The One-Pot Multienzyme (OPME) Synthesis of Human Blood Group H Antigens and A Human Milk Oligosaccharide (HMOS) with Highly Active *Thermosynechococcus elongates* alpha1–2-Fucosyltransferase. *Chem. Commun* 2016, 52, 3899–3902.
- (20). Yu H; Li Y; Zeng J; Thon V; Nguyen DM; Ly T; Kuang HY; Ngo A; Chen X Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans. *J. Org. Chem* 2016, 81, 10809–10824. [PubMed: 27736072]

- (21). Craft KM; Townsend SD Synthesis of Lacto-N-Tetraose. *Carbohydr. Res* 2017, 440–441, 43–50.
- (22). Yu H; Thon V; Lau K; Cai L; Chen Y; Mu S; Li Y; Wang PG; Chen X Highly Efficient Chemoenzymatic Synthesis of beta1–3-Linked Galactosides. *Chem. Commun* 2010, 46, 7507–7509.
- (23). Malekan H; Fung G; Thon V; Khedri Z; Yu H; Qu J; Li Y; Ding L; Lam KS; Chen X One-Pot Multi-Enzyme (OPME) Chemoenzymatic Synthesis of Sialyl-Tn-MUC1 and Sialyl-T-MUC1 Glycopeptides Containing Natural or Non-natural Sialic Acid. *Bioorg. Med. Chem* 2013, 21, 4778–4785. [PubMed: 23535562]
- (24). Murata T; Inukai T; Suzuki M; Yamagishi M; Usui AT Facile Enzymatic Conversion of Lactose into Lacto-*N*-Tetraose and Lacto-*N*-Neotetraose. *Glycoconj. J* 1999, 16, 189–195. [PubMed: 10596893]
- (25). Henze M; Schmidtke S; Hoffmann N; Steffens H; Pietruszka J; Elling L Combination of Glycosyltransferases and a Glycosynthase in Sequential and One-Pot Reactions for the Synthesis of Type 1 and Type 2 N-Acetyllactosamine Oligomers. *ChemCatChem* 2015, 7, 3131–3139.
- (26). Schmolzer K; Weingarten M; Baldenius K; Nidetzky B Lacto-*N*-tetraose Synthesis by Wild-Type and Glycosynthase Variants of The beta-N-hexosaminidase from *Bifidobacterium bifidum*. *Org. Biomol. Chem* 2019, 17, 5661–5665. [PubMed: 31094393]
- (27). Li W; McArthur JB; Chen X Strategies for Chemoenzymatic Synthesis of Carbohydrates. *Carbohydr. Res* 2019, 472, 86–97. [PubMed: 30529493]
- (28). Liu XW; Xia C; Li L; Guan WY; Pettit N; Zhang HC; Chen M; Wang PG Characterization and Synthetic Application of A Novel beta1,3-Galactosyltransferase from *Escherichia coli* O55:H7. *Bioorg. Med. Chem* 2009, 17, 4910–4915. [PubMed: 19560364]
- (29). Baumgartner F; Conrad J; Sprenger GA; Albermann C Synthesis of The Human Milk Oligosaccharide Lacto-*N*-Tetraose in Metabolically Engineered, Plasmid-Free *E. coli*. *Chembiochem* 2014, 15, 1896–1900. [PubMed: 25044565]
- (30). Baumgartner F; Sprenger GA; Albermann C Galactose-Limited Fed-Batch Cultivation of *Escherichia coli* for The Production of Lacto-*N*-Tetraose. *Enzyme Microb. Technol* 2015, 75–76, 37–43.
- (31). Baumgartner F; Jurzitza L; Conrad J; Beifuss U; Sprenger GA; Albermann C Synthesis of Fucosylated Lacto-*N*-tetraose Using Whole-Cell Biotransformation. *Bioorg. Med. Chem* 2015, 23, 6799–6806. [PubMed: 26481658]
- (32). Fischoder T; Laaf D; Dey C; Elling L Enzymatic Synthesis of N-Acetyllactosamine (LacNAc) Type 1 Oligomers and Characterization as Multivalent Galectin Ligands. *Molecules* 2017, 22, 1320.
- (33). Fischoder T; Cajic S; Reichl U; Rapp E; Elling L Enzymatic Cascade Synthesis Provides Novel Linear Human Milk Oligosaccharides as Reference Standards for xCGE-LIF Based High-Throughput Analysis. *Biotechnol. J* 2019, 14, e1800305. [PubMed: 30076755]
- (34). Fischoder T; Cajic S; Grote V; Heinzler R; Reichl U; Franzreb M; Rapp E; Elling L Enzymatic Cascades for Tailored (13)C6 and (15)N Enriched Human Milk Oligosaccharides. *Molecules* 2019, 24, 3482.
- (35). Madeira F; Park YM; Lee J; Buso N; Gur T; Madhusoodanan N; Basutkar P; Tivey ARN; Potter SC; Finn RD; Lopez R The EMBL-EBI Search and Sequence Analysis Tools APIs in 2019. *Nucleic Acids Res.* 2019, 47, W636–W641. [PubMed: 30976793]
- (36). Altschul SF; Gish W; Miller W; Myers EW; Lipman DJ Basic Local Alignment Search Tool. *J. Mol. Biol* 1990, 215, 403–410. [PubMed: 2231712]
- (37). Boix E; Zhang Y; Swaminathan GJ; Brew K; Acharya KR Structural Basis of Ordered Binding of Donor and Acceptor Substrates to The Retaining Glycosyltransferase, alpha-1,3-Galactosyltransferase. *J. Biol. Chem* 2002, 277, 28310–28318. [PubMed: 12011052]
- (38). Li Y; Yu H; Chen Y; Lau K; Cai L; Cao H; Tiwari VK; Qu J; Thon V; Wang PG; Chen X Substrate Promiscuity of N-Acetylhexosamine 1-Kinases. *Molecules* 2011, 16, 6396–6407. [PubMed: 21799473]
- (39). Chen Y; Thon V; Li Y; Yu H; Ding L; Lau K; Qu J; Hie L; Chen X One-Pot Three-Enzyme Synthesis of UDP-GlcNAc Derivatives. *Chem. Commun* 2011, 47, 10815–10817.

- (40). Lau K; Thon V; Yu H; Ding L; Chen Y; Muthana MM; Wong D; Huang R; Chen X Highly Efficient Chemoenzymatic Synthesis of beta1–4-Linked Galactosides with Promiscuous Bacterial beta1–4-Galactosyltransferases. *Chem. Commun* 2010, 46, 6066–6068.
- (41). Li Y; Xue M; Sheng X; Yu H; Zeng J; Thon V; Chen Y; Muthana MM; Wang PG; Chen X Donor Substrate Promiscuity of Bacterial beta1–3-N-Acetylglucosaminyltransferases and Acceptor Substrate flexibility of beta1–4-Galactosyltransferases. *Bioorg. Med. Chem* 2016, 24, 1696–1705. [PubMed: 26968649]
- (42). Chen M; Chen LL; Zou Y; Xue M; Liang M; Jin L; Guan WY; Shen J; Wang W; Wang L; Liu J; Wang PG Wide Sugar Substrate Specificity of Galactokinase from *Streptococcus pneumoniae* TIGR4. *Carbohydr. Res* 2011, 346, 2421–2425. [PubMed: 21903203]
- (43). Muthana MM; Qu J; Li Y; Zhang L; Yu H; Ding L; Malekan H; Chen X Efficient One-Pot Multienzyme Synthesis of UDP-Sugars Using A Promiscuous UDP-Sugar Pyrophosphorylase from *Bifidobacterium longum* (BLUSP). *Chem. Commun* 2012, 48, 2728–2730.
- (44). Thurl S; Munzert M; Henker J; Boehm G; Muller-Werner B; Jelinek J; Stahl B Variation of Human Milk Oligosaccharides in Relation to Milk Groups and Lactational Periods. *Br. J. Nutr* 2010, 104, 1261–1271. [PubMed: 20522272]
- (45). Bode L; Jantscher-Krenn E Structure-Function Relationships of Human Milk Oligosaccharides. *Adv. Nutr* 2012, 3, 383s–391s. [PubMed: 22585916]
- (46). Yi W; Liu X; Li Y; Li J; Xia C; Zhou G; Zhang W; Zhao W; Chen X; Wang PG Remodeling Bacterial Polysaccharides By Metabolic Pathway Engineering. *Proc. Natl. Acad. Sci. U. S. A* 2009, 106, 4207–4212. [PubMed: 19251666]
- (47). Chaturvedi P; Warren CD; Altaye M; Morrow AL; Ruiz-Palacios G; Pickering LK; Newburg DS Fucosylated Human Milk Oligosaccharides Vary Between Individuals and Over The Course of Lactation. *Glycobiology* 2001, 11, 365–372. [PubMed: 11425797]
- (48). Kunz C; Rudloff S; Schad W; Braun D Lactose-Derived Oligosaccharides in The Milk of Elephants: Comparison with Human Milk. *Br. J. Nutr* 1999, 82, 391–399. [PubMed: 10673912]
- (49). Yu H; Yu H; Karpel R; Chen X Chemoenzymatic Synthesis of CMP-sialic Acid Derivatives by a One-Pot Two-Enzyme System: Comparison of Substrate Flexibility of Three Microbial CMP-sialic Acid Synthetases. *Bioorg. Med. Chem* 2004, 12, 6427–6435. [PubMed: 15556760]
- (50). Sugiarto G; Lau K; Qu J; Li Y; Lim S; Mu S; Ames JB; Fisher AJ; Chen X A Sialyltransferase Mutant with Decreased Donor Hydrolysis and Reduced Sialidase Activities for Directly Sialylating LewisX. *ACS Chem. Biol* 2012, 7, 1232–1240. [PubMed: 22583967]
- (51). Coppa GV; Pierani P; Zampini L; Carloni I; Carlucci A; Gabrielli O Oligosaccharides in Human Milk During Different Phases of Lactation. *Acta Paediatr. Suppl* 1999, 88, 89–94.
- (52). Xu HT; Zhao YF; Lian ZX; Fan BL; Zhao ZH; Yu SY; Dai YP; Wang LL; Niu HL; Li N; Hammarstrom L; Boren T; Sjoström R Effects of Fucosylated Milk of Goat and Mouse on *Helicobacter pylori* Binding to Lewis b Antigen. *World J. Gastroenterol* 2004, 10, 2063–2066. [PubMed: 15237435]
- (53). Yu H; Santra A; Li Y; McArthur JB; Ghosh T; Yang X; Wang PG; Chen X Streamlined Chemoenzymatic Total Synthesis of Prioritized Ganglioside Cancer Antigens. *Org. Biomol. Chem* 2018, 16, 4076–4080. [PubMed: 29789847]
- (54). Engels L; Elling L WbgL: A Novel Bacterial α 1,2-Fucosyltransferase for the Synthesis of 2'-Fucosyllactose. *Glycobiology* 2014, 24, 170–178. [PubMed: 24249735]
- (55). Bering SB Human Milk Oligosaccharides to Prevent Gut Dysfunction and Necrotizing Enterocolitis in Preterm Neonates. *Nutrients*. 2018, 10, 1461







Figure 1. Structures of HMOs that are synthesized in this work (1–6) and three LNT-containing HMOs synthesized previously (7–9).^{1, 18–20}

**Scheme 1.**

Preparative-scale sequential one-pot multienzyme (OPME) synthesis of LNT (1).

**Scheme 2.**

Preparative-scale one-pot multienzyme (OPME) synthesis of LNT-containing fucosides (2–4, and 8) from LNT (1).

**Scheme 3.**

Preparative-scale sequential OPME synthesis of LNT-containing fucosides (5 and 6) from GlcNAcβ3Galβ4Glc (LNT II).

Table 1.Kinetic Constants for Cv β 3GalT and EcWbgO.

| Enzyme | Substrate | k_{cat} (min^{-1}) | K_{m} (mM) | $k_{\text{cat}}/K_{\text{m}}$ ($\text{min}^{-1} \text{mM}^{-1}$) |
|---------------------|---------------------------|--|----------------------|--|
| Cv β 3GalT | LNT II- β ProNHFmoc | $(2.9 \pm 0.1) \times 10^2$ | 0.74 ± 0.07 | 3.9×10^2 |
| | UDP-Gal | 79 ± 4 | 0.23 ± 0.06 | 3.4×10^2 |
| EcWbgO ^a | GlcNAc | 2.55 | 0.32 | 7.89 |
| | LNT II | 2.50 | 5.5×10^{-2} | 16.7 |
| | UDP-Gal | 13.90 | 3.4 | 4.09 |

^aReported previously²⁸.